Abstract 1669P
Background
Studies have shown that patients with cervical intraepithelial neoplasia (CIN) linked to human papillomavirus (HPV) experience shame and/or guilt due to the association of HPV with sexual transmission. Likewise, such feelings were also reported by cervical cancer (CC) patients. Understanding the similarities or differences in the relationship between guilt, shame, and quality of life (QoL) among these two groups might shed light on effective psychosocial interventions.
Methods
The study employed a cross-sectional design. Patients diagnosed with CIN (n=105, 11.42% CIN 1, 15.23% CIN 2, 58.09% CIN 3, 8.57% unknown) and CC (n=87, 16.09% stage 1, 17.24% stage 2, 36.78% stage 3, 8.04% stage 4, 8.04% were diagnosed with CIN that later progressed, 8.04% were uncertain about their stage at diagnosis, 5.74% unknown) who were recruited through social networks specific to CIN and CC patients completed self-report questionnaires assessing demographic information, medical history, QoL, and feelings of shame and guilt.
Results
The preliminary results revealed a significant negative association between both guilt and shame and QoL in both groups. However, no significant difference in QoL was found between CIN and CC patients (57.12, 52.26 respectively, p=0.1). Additionally, a significant higher level of guilt was reported by CIN patients (13.42) compared to CC patients (10.26) (d=0.58, p=0.0001). There was no significant difference in shame reported by CIN patients compared to CC patients (12.8, 11.37 respectively, p=0.07).
Conclusions
The findings underscore the detrimental role of shame and guilt in the perception of QoL of patients with CIN and CC. Addressing these negative feelings through targeted interventions may be crucial for improving overall well-being in these populations and enhancing their coping mechanisms. Further research involving a larger sample size may provide deeper insights into the differences and similarities between CIN and CC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar - Israel Women's Cancer Association (RA) in collaboration with Ariel University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11